Sophia Antipolis, France, 13 July 2006:
Italian heart specialists are calling on health care providers throughout Europe to give urgent consideration to introducing ECG screening for all babies at around three to four weeks of age to pick up a life-threatening genetic condition called long QT syndrome.
Evidence they have gathered from ECGs in a just completed and still unpublished prospective study of 45,000 infants, coupled with a cost-effectiveness analysis, has demonstrated that significant numbers of sudden deaths could be prevented for less than €12,000 per year-of-life saved.
The findings from the cost analysis study are published on-line today (Thursday 13 July) in the European Heart Journal (1), the journal of the European Society of Cardiology.
The study, led by Professor Peter J. Schwartz of the University of Pavia and IRCCS Policlinico San Matteo, focused on the inherited condition long QT syndrome (LQTS), a disorder of the electrical rhythm of the heart (2). It rarely produces symptoms but is a leading cause of sudden death in children and young adults, and when it occurs in infants their deaths are usually mislabelled as sudden infant death syndrome (SIDS).
In fact, Professor Schwartz and associates have recently completed a study on over 200 victims of SIDS from Norway and have found genetic mutations diagnostic for long QT syndrome in almost 10%. This indicates that early treatment of LQTS would also prevent some deaths regarded as SIDS because, once detected, it can be successfully treated in most cases with medication by beta-blockers, or occasionally by sympathetic denervation (3) or the use of implantable defibrillators.
Although the focus of the 45,000-infant study was to identify babies with LQTS, the research also unexpectedly revealed four cases involving two other life-threatening heart conditions – coarctation of the aorta and anomalous origin of the left coronary artery from the pulmonary artery (ALCAPA) (4) – which had gone undetected in initial neonatal checks. This finding led directly to the researchers extending their cost-effectiveness analysis to include these two congenital heart diseases.
Professor Schwartz, who is chairman of the department of cardiology, said: “Our study clearly demonstrates that neonatal ECG screening is highly cost-effective and that a significant number of lives can be saved – possibly up to 230-250 a year, for example, in the 15 countries of the pre-enlarged EU – for an objectively small cost. The time is ripe for those involved in the administration of public health to consider the implementation by the National Health Services of such a programme, with the objective of reducing the number of preventable sudden cardiac deaths in infants, children and young adults.”
He said that although there could be some differences in specific costs in different countries, their calculation for its introduction in Italy varied all probabilities and costs by plus or minus 30% so as to be valid for most European countries.
There have been various estimates in the medical literature in the past about the prevalence of LQTS, with figures ranging from one in 5,000 to one in 20,000, but none was based on actual data. The Pavia team’s research is the first large prospective study on an unselected population. They performed ECG between days 15 and 25 in 45,000 babies and found a markedly prolonged QT interval in almost one in 1,000 (0.9). In more than 50% of these infants Professor Schwartz has identified gene mutations responsible for LQTS. “Therefore this means that the prevalence is probably around one in 2,500 – higher than previous estimates,” he said.
“The cost per year-of-life saved by identifying and treating LQTS is really very low – €11,740: for saving one entire life of 70 years we are looking at just €820,000. When, to account for what happens in the real world, we also consider the two other congenital heart diseases that routine ECG screening can pick up, then the cost per year-of-life saved is only just over €7,000 or around €490,000 over a 70-year lifetime.”
He said that 220 out of 550,000 newborns per year (in Italy) are affected by LQTS. Without screening 13.5% (30) would die early. But screening would cut this to 3.2% (7), saving 23 lives a year. Additionally, screening would prevent four more deaths due to the two congenital heart diseases. In total therefore, screening in Italy would save an estimated 27 lives a year from the three conditions combined.
Professor Schwartz outlined the potential clinical benefits of screening for LQTS:
- we can treat the baby, protecting it from life-threatening arrhythmias, thus reducing deaths in childhood and later years as well;
- we can identify other family members affected by LQTS who are at risk of sudden death as well;
- by treating all the infants who show manifest LQTS, we would also protect those at risk of dying in the first few months of life and whose deaths would be labelled ‘SIDS’;
- in addition, our unexpected finding of these two other conditions means we have an opportunity to pick up the few, but life-threatening cases of congenital heart diseases that might escape routine medical checks, for which surgery can radically change the prognosis.
“Parents of a newborn child have the right to know about the existence of an uncommon disease, which is potentially lethal but for which effective and safe treatments exist, and which can be diagnosed by a simple ECG. European citizens and taxpayers also need to be informed about what is possible to do, and at what cost, to reduce the tragic burden of sudden deaths in the young,” Professor Schwartz concluded.
A PDF of the full report is available on request
The European Heart Journal is an official journal of the European Society of Cardiology. Please acknowledge the journal as a source in any articles.
The European Society of Cardiology (ESC)
The ESC represents more than 50,000 cardiology professionals across Europe and the Mediterranean. Its mission is to improve the quality of life of the European population by reducing the impact of cardiovascular disease.
The ESC achieves this through a variety of scientific and educational activities including the coordination of: clinical practice guidelines, education courses and initiatives, pan-European surveys on specific disease areas and the ESC Annual Congress, the largest medical meeting in Europe. Furthermore, the ESC promotes cardiovascular disease prevention messages to the general public, most notably during its annual ‘For Your Heart’s Sake’ event, a fun yet educational event offering risk assessment and prevention advice, held in parallel to the Congress each year.
The ESC comprises 2 Councils, 4 Associations, 23 Working Groups and 49 National Cardiac Societies. Both the ESC Congress and ‘For Your Heart’s Sake’ take place in late August/early September each year in a European ‘Heart-Healthy City’. The ESC Congress 2006, to be held from 2-6 September in Barcelona, Spain, will be a joint meeting with the World Heart Federation's XVth World Congress of Cardiology.
The ESC administrative headquarters are based at the European Heart House, Sophia Antipolis, France.